In a multinational, placebo-controlled, double-blind trial, the selective vitamin D receptor activator paricalcitol (Zemplar, Abbott Laboratories), at doses of 1 µg or 2 µg daily, reduced albuminuria in patients with type 2 diabetes, who were already being treated with renin-angiotensin-aldosterone system inhibitors.
In a multinational, placebo-controlled, double-blind trial, the selective vitamin D receptor activator paricalcitol (Zemplar, Abbott Laboratories), at doses of 1 µg or 2 µg daily, reduced albuminuria in patients with type 2 diabetes, who were already being treated with renin-angiotensin-aldosterone system inhibitors. This research was published online November 4 in The Lancet, HealthDay News reported.
The primary end point was the percentage change in geometric mean urinary albumin-to-creatinine ratio (UACR) for the combined paricalcitol groups versus the placebo group.
The combined paricalcitol treatment group had a non-statistically significant between-group difference versus placebo of −15%; the 1-µg and 2-µg treatment groups had between-group differences versus placebo of −11% (P=.23) and −18% (P=.053), respectively. Early, sustained reductions in UACR was seen in the 2-µg paricalcitol group (P=.014 vs placebo). All groups had UACR reductions, including the placebo group.
Dick de Zeeuw, MD, of the University of Groningen, Netherlands, and lead researcher, told Formulary that future studies with renal outcomes should be conducted to prove paricalcitol’s renal and cardiovascular protective effects.
Abbott Laboratories funded the study, and several authors disclosed financial ties to the company, as well as to other pharmaceutical and/or medical device companies.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More